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CURRENT PRACTICES AND PERSPECTIVES OF GENETIC COUNSELORS AND 
REPRODUCTIVE ENDOCRINOLOGISTS REGARDING TRANSFER OF MOSAIC 
EMBRYOS 
Angelica Palma Starnes, B.S.  
Advisory Professor: Jennifer Czerwinski, M.S., CGC 
With the recent transition in testing methodology used for preimplantation genetic testing for aneuploidy 
(PGT-A) from array comparative genomic hybridization to next generation sequencing, mosaic embryos 
are being identified more readily. Given the limited clinical guidance and information regarding 
outcomes after the transfer of mosaic embryos (TME), a mosaic test result can present challenging 
scenarios for providers and patients. The current landscape of this area of reproductive medicine must be 
described before a consensus can be determined and areas for improvement can be identified. This cross-
sectional descriptive study aimed to define the current practices regarding TME as reported by prenatal 
and/or infertility genetic counselors (GCs) and reproductive endocrinologists (REs). In addition, it aimed 
to determine GCs’ and REs’ perspectives on patient education, informed consent, decision making and 
clinical guidance with regard to the TME.  An invitation to participate in the electronic survey was 
distributed to GCs through the National Society of Genetic Counselors listserv and to REs via an email 
from the principal investigator. A total of 223 responses were analyzed consisting of 194 GCs and 29 
REs. Data analysis showed that infertility GCs practices and perspectives were more consistent with REs 
than non-infertility GCs. However, regardless of specialty, responses showed little to no consensus 
among providers regarding their perspectives on this topic. Overall, respondents reported feeling more 
comfortable with pre-test PGT-A counseling compared to counseling about TME. Furthermore, a 
majority of respondents indicated that additional consensus and/or guidance is needed for several topics 
related to TME, such as when to discuss the possibility of mosaic embryos with patients, when the 
decision should be made whether or not to transfer mosaic embryos and prioritization when multiple 
iv 
 
mosaic embryos are available. These results support the urgent need for additional consensus and 
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        In vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) of 
embryos is a rapidly evolving area of reproductive medicine that has become progressively accessible 
and advanced in the last several years. With the transition in testing methodology from array comparative 
genomic hybridization (CGH) to next generation sequencing (NGS), mosaic embryos are being more 
readily identified prior to transfer. One important limitation of PGT-A is that the results are only 
representative of the genetic makeup of the cells biopsied from the embryo and may not always be 
reflective of the genetic makeup of the entire embryo. Given the limitations of embryo sampling, 
embryos that yield mosaic test results are thought to be at risk for fetal mosaicism, but it cannot be 
definitively determined that the transfer would result in a mosaic fetus. Furthermore, PGT-A results 
cannot determine the level of mosaicism in the entire embryo or whether the mosaicism is isolated to the 
trophoectoderm or is also present in the inner cell mass. For those patients who are left with only mosaic 
test results after PGT-A, the decision must be made to either transfer a potentially mosaic embryo, 
accepting the associated risks and uncertain outcome, begin another cycle, or discontinue their IVF 
experience without a transfer.  
In 2015, a letter to the editor of The New England Journal of Medicine titled, Healthy Babies after 
Intrauterine Transfer of Mosaic Aneuploid Blastocysts outlined 18 pregnancies with a normal karyotype 
on chorionic villus testing after transfer of one or more mosaic embryos that resulted in the birth of full-
term [apparently] healthy infants (Greco et al. 2015). This letter started a discussion amongst health care 
providers about whether they should be offering the option to transfer a mosaic embryo(s) to patients 
who may have no euploid embryos following PGT-A. Although some clinical practices have elected to 
consider transfer of mosaic embryos, others remain hesitant. This hesitation is presumably due to the 
potential risks of transferring mosaic embryos. In addition, the limited and sometimes conflicting data 
that has been published regarding transfer of mosaic embryos and the expected pregnancy outcomes has 
added to this hesitation (Kushnir et al., 2018; Harton et al., 2017). There has been research analyzing 
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how various factors of the mosaic finding may affect ongoing pregnancy rates. One study found no 
significant difference in the ongoing pregnancy rates between embryos with a single mosaic monosomy 
versus a single mosaic trisomy (Munne et al. 2017). Additionally, some studies have presented data 
suggesting that embryos with a lower percentage of the abnormal cell line in the biopsied sample have a 
higher ongoing pregnancy rate than embryos with biopsies comprised of a higher percentage of the 
abnormal cell line (Munne, 2017; Spinella et al., 2018). Contrary to this finding, other studies have 
shown that the percentage of abnormal cells in the trophectoderm biopsy does not necessarily correlate 
with the percentage of abnormal cells in the inner cell mass, which eventually becomes the fetus (Taylor, 
2015). In addition, Victor et al. (2019) reported on the transfer of 100 mosaic embryos and did not find 
any correlation between percentage of mosaicism in the biopsy and ongoing pregnancy rates. When 
evaluating live birth rates following the transfer of a mosaic embryo(s), Fragouli et al. (2017) showed 
that the live birth rate was significantly lower (27.3%) when compared with transfer of an embryo with 
normal PGT-A testing (47%). Furthermore, when separated by the type of mosaic PGT-A result, the 
same study showed that embryos with segmental or partial mosaicism had a live birth rate that was 
slightly lower or comparable to transfer of euploid embryos, whereas whole chromosome mosaicism and 
complex mosaicism resulted in a live birth less frequently.  
In addition to several publications addressing the advancing technology of PGT-A, the 
Preimplantation Genetic Diagnosis International Society (PGDIS, 2016) and the Congress for 
Controversies in Preconception, Preimplantation and Prenatal Diagnosis (CoGEN, 2016) have put forth 
position statements on this topic. These position statements are similar to one another in their 
recommendations. Specifically, they recommend providers should consider transfer when there are no 
euploid embryos and no option for undergoing another IVF cycle. They suggest prioritizing mosaic 
embryos based on the percentage of the aneuploid cell line (lower levels preferable), whether they are 
mosaic for trisomy vs. monosomy (monosomy preferable) and then based on which chromosome is 
aneuploid. They also provide some brief guidance for laboratories performing the testing and clinicians 
providing counseling. Of note, these position statements are not evidence-based or peer-reviewed, but 
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rather a product of discussion amongst these organizations’ membership. Sachdev et al. (2017) and 
Munne et al. (2017) cited these position papers and agreed with several recommendations put forth but 
also acknowledged that the guidance should be reviewed in light of recent studies providing 
contradictory information. Munne suggests that these guidelines may be overly cautious, but a 
conservative approach is understandable given the scarcity of data available. In contrast to these position 
papers, Grati et al. published An Evidence-based Scoring System for Prioritizing Mosaic Embryos 
Following Preimplantation Genetic Screening in April of 2018. This put forth a different prioritization 
scheme with a specific risk for each chromosome. This was a retrospective study that included 
cytogenetic and molecular testing results from over 72,000 chorionic villi samples and over 3,000 
products of conception. Currently, there have been no studies to determine how much and in what 
manner these publications are being utilized by providers to counsel patients and guide decision making. 
Given the small amount of data and guidance in this emerging area, there are unique challenges for 
patients trying to make reproductive decisions as well as their providers who are charged with providing 
recommendations and counseling. Some examples of the potential dilemmas faced by patients include 
added difficulty in deciding whether or not to pursue PGT-A (Gebhart et al., 2016), using complex and 
often uncertain testing information to make reproductive decisions in a high pressure or sometimes time-
sensitive manner, feelings of regret about pursuing testing after receiving uncertain results (Bernhardt et 
al., 2012) and/or additional decision-making burden regarding transfer or storage of mosaic embryos 
(Besser et., 2017). 
Providers also face several challenges both before and after a patient’s decision to pursue testing 
and to transfer mosaic embryos. Some of these challenges are due to the absence of negative or positive 
predictive values for PGT-A results, contradictory data regarding best practice for prioritization when 
multiple mosaic embryos are available, and limited outcome data to provide anticipatory guidance. 
Variability amongst labs regarding the thresholds for reporting mosaicism and what information is 
reported/excluded, and/or challenges collecting outcome data also create complexities for providers. 
Providers may also have difficulty determining what time point is most appropriate for counseling and/or 
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consenting the patient about the risks and limitations of transferring a mosaic embryo(s), obtaining 
informed consent to transfer and determining recommendations for the most appropriate prenatal testing 
plan following established viability.  
There is currently no consensus between healthcare providers regarding the best practices with 
respect to the transfer of mosaic embryos.  Outside of the position statements put forth by PGDIS and 
CoGEN, there is limited guidance for providers who are faced with these cases. Two such groups of 
health care providers that are currently navigating this new era are genetic counselors (GCs) and 
reproductive endocrinologists (REs). There is limited literature discussing the clinical experience of 
transferring mosaic embryos and the role of GCs and REs in the education and consent process. While 
Besser et al. (2017) outlined the genetic counseling considerations, there is little known about the current 
practices and perspectives of healthcare providers regarding the transfer of mosaic embryos. The current 
landscape of this field must be described before a consensus can be determined and areas for 
improvement can be identified. In an effort to address this gap in knowledge, this study aimed to 
descirbe current practices regarding transfer of mosaic embryos, as reported by GCs and REs. In 
addition, it aimed to determine GC and RE perspectives on patient education, informed consent, decision 






Study Design  
This cross-sectional descriptive study surveyed two populations of health care providers involved 
in the IVF and PGT-A process: GCs and reproductive endocrinologists REs.  More specifically, eligible 
participants consisted of practicing prenatal, preconception and/or infertility GCs, along with practicing 
REs and fellows enrolled in RE fellowship programs in the United States. This research project was 
approved by the Committee for the Protection of Human Subjects (CPHS) of the University of Texas 
Health Science Center at Houston (HSC-MS-18-0566). Responses were collected from September 25th, 
2018 to March 15th, 2019. GCs were accessed through the National Society of Genetic Counselors 
(NSGC).  An invitation to participate in the online survey was sent out to the NSGC membership listserv 
three times over the course of the data collection period. GCs were allowed to forward the survey to 
other GCs who may not have received the survey invitation email from NSGC. In addition, GCs were 
allowed to forward the email survey invitation to REs that they work with or provide their email 
address(es). An email invitation to participate was then sent to any RE’s email address provided by a 
participating GC.  Additionally, a recruitment email to participate in the survey was sent out twice to 104 
RE fellowship program directors and faculty within the United States. REs were also allowed to forward 
the survey to other REs or RE fellows. Initially, an attempt to distribute the study invitation to REs 
through the Society of Reproductive Endocrinology and Infertility listserv was made; however, this 
recruitment method was unsuccessful.  
In order to encourage participation and promote awareness for the study, an announcement was 
made at the assisted reproductive technologies and infertility special interest group meeting at the Annual 
Education Conference held by the National Society of Genetic Counselors on November 14th, 2018. At 
this meeting, attendees were alerted to the survey and provided a paper handout with basic information 
about the study and instructions on how to participate. All participants who completed the survey, 
regardless of recruitment method, were given the opportunity to provide their email address to be entered 




The online survey tool, Qualtrics, was used to create and administer the survey (Qualtrics 2015). 
The survey was an investigator-designed, non-validated questionnaire consisting of various question 
formats that included free response, Likert scale, multiple-select and multiple-choice. Although the 
survey was not validated, it was piloted by 4 genetic counseling students for timing and readability. The 
number of questions a participant was given varied and was dependent on their area of practice (prenatal 
and/or infertility GC or RE) and their answers to particular gateway questions. On average, the survey 
should have taken no more than 15 minutes to complete. The survey questions were split up into 5 main 
sections: introduction to the study and consent, demographics, GC experience (GCs only), RE experience 
(REs only), confidence/decision-making/consenting, and resources/guidance. The GC and RE experience 
sections focused on determining providers’ current practices in cases involving transfer of mosaic 
embryos. The remainder of the questions aimed to determine providers’ perspectives regarding their 
confidence level counseling patients on this topic, the patient decision-making process, consenting of 
patients, utilization of existing resources/guidance and need for additional resources/guidance.  
Data Analysis  
Survey responses were collected electronically (Qualtrics, Provo, UT) and were anonymous. The 
responses were then coded into a Microsoft Excel file and stored on a secure server. Any respondents 
who only completed demographic information were excluded from data analysis. Data analysis was 
conducted with STATA (v.130, College Station, TX). Comparisons within and between clinical groups 
were conducted using rank sum, chi-square, Spearman’s correlation or Fisher exact tests for categorical 
data and Kruskal-Wallis test with a post-hoc Dunn’s test for interval data. Statistical significance was 







Of the 273 respondents that accessed the survey, 223 met the inclusion criteria and answered at least 
one question.  One hundred and ninety-four of these respondents identified as GCs while 29 identified as 
REs. (Figure 1). Since answers were not required for every question, the number of respondents can vary 
between questions. Refer to tables for the number of respondents who provided an answer for each 
question. 
 
Figure 1: Respondent flowchart describing GC and RE cohorts  
Using the most recent professional status survey (PSS) published by National Society of Genetic 
Counselors in 2018 as an estimate, there were approximately 1,800 GCs who received the survey and 
were eligible to participate (currently practicing prenatal, preconception and/or infertility GC). Our 
responses reflect an 11% response rate from GCs. The active RE recruitment email was sent to 110 
practicing REs. Prior to this email being sent out, we had collected 18 RE responses. These 18 
individuals presumably received the survey invitation from a GC colleague. After sending out the 
recruitment email twice, we collected an additional 11 RE responses. This reflects an estimated 10% 
response rate amongst invited practicing REs. Of the 29 RE responses, 20 identified as practicing and 9 
273 responses 
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9 fellows 20 practicing 
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identified as fellows.  It is difficult to determine the response rate for RE fellows because the total 
number of RE fellows in the United States can fluctuate from year to year. Also, the recruitment email 
was not sent directly to fellows but to program directors and faculty members. Although we invited them 
to forward the survey invitation to fellows, we do not know how many fellows received an invitation to 
participate. Approximately half (48%) of GCs selected prenatal as their only specialty while 13% 
selected infertility/ART as their only specialty.  Thirty-eight percent of GCs reported more than one 
specialty. The proportion of preconception counselors in our cohort (39%), whether it was the only 
specialty reported or reported in combination with another specialty, was comparable with the estimate 
of preconception GCs reported in the 2018 NSGC PSS (36%). However, the proportion of prenatal GCs 
included in our study (81%) was overly representative of the proportion of prenatal GCs reported in the 
PSS (64%). The PSS did not provide information regarding the proportion of GCs who identify as 
infertility counselors.  
GCs from 34 states participated with most practicing in California (24), New York (22) or Texas 
(21). The majority of responding REs practice in Texas (14). We collected one response from an RE who 
practices outside of the United States. The GC cohort predominantly reported less than five years of 
experience (60%) with a decrease in number of respondents as years of experience increased. The RE 
cohort consisted of nine fellows and 20 practicing REs with practicing REs most commonly reporting 
less than five years of experience (24%) and being one of five to nine REs in their practice (48%).  GCs 
most commonly reported working in a group of two to four counselors (38%), followed by 22% 
reporting a total of five to nine GCs and 20% indicating they are the only GC at their institution within 





n (%), n = 194 
REs 
n (%), n = 29 
Years working in specialty    
Fellow 0 9 (31) 
<5 116 (59.8) 7 (24.1) 
5-9 34 (17.5) 3 (10.3) 
10-14 20 (10.3) 1 (3.4) 
15-19 14 (7.2) 1 (3.4) 
20-24 7 (3.6) 2 (6.9) 
25-29 0 3 (10.3) 
≥30 0 3 (10.3) 
No response/blank 3 (1.5) 0 
Total GCs/REs in clinic within specialty    
1 39 (20.3) 0  
2-4 72 (37.5) 6 (20.6) 
5-9 43 (22.4) 14 (48.3) 
10-14 21 (10.9) 5 (17.2) 
15-19 12 (6.3) 0  
20-29 1 (0.5) 1(3.4) 
30-39 1 (0.5) 0 
40-49 1 (0.5) 0 
≥50  2 (1) 0 
No response/blank 2 (1) 3 (10.3) 
GC work setting (check all that apply)   
Academic institution   89 - 
Nonacademic institution  61 - 
Private clinic 33 - 
IVF clinic 15 - 
Other 16 - 
No response/blank  2 - 
Table 1: Practice information of respondents   
 
Current practices and experience regarding PGT-A and transfer of mosaic embryos  
 All but one RE reported that their clinic offers PGT-A to their patients. The one RE who does 
not offer PGT-A was a fellow who does not practice in the United States, and this participant specified 
that the reason for this is due to clinic policy. Among those who offer PGT-A, just over half (54%) offer 
it to all their patients, while the remaining were split between those that offer testing only if the patient 
meets specific criteria (25%) or if the patient is of a certain age (21%) (Table 2). Nearly all of these REs 
(93%) offer this test to patients at least once a week.  Most GCs (80%) report that they do see patients to 
discuss PGT-A (Table 3). There was variability with regard to the frequency that PGT-A is offered based 
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on the GC specialty. GCs who identify with infertility as their only specialty or one of multiple 
specialties they practice (Infertility GCs) offered PGT-A significantly more frequently with 67% offering 
PGT-A at least once per week compared to six percent of prenatal only GCs and 19% of GCs who 
identify as prenatal/preconception counselors (p<0.001).  Of the 156 GCs who reported counseling about 
PGT-A, 153 provided a response regarding whether they see these patients before testing, after testing or 
both before and after testing. Of those 153 GCs, they typically see patients either before testing only 
(37%) or both before and after testing (37%) to discuss the option of PGT-A.  REs most commonly 
report (89%) that they conduct pre-test counseling themselves while 18% utilize a lab GC.  Only one RE 
reports referring to an outside/contracted clinical GC. This was significantly different when compared to 
who conducts the post-test/pre-transfer counseling (p<0.001) with REs providing this less frequently 
(29%) than pre-test counseling and instead, utilize contracted outside clinical GCs (27%) and lab GC 
(24%) more often post-test/pre-transfer. REs most commonly report (43%) that about 51-75% of their 
patients elect PGT-A. Eighty-two percent of REs who offer PGT-A have received a report with no 
normal embryos but one or more mosaic embryos. Most of these REs (65%) estimated that 1-10% of 






Circumstance under which PGT-A is offered  n = 28 
Offer to all 15 (54) 
Offer to all of certain age 6 (21) 
Only offer to patients who meet specific criteria 7 (25) 
Never offer 0 
Frequency PGT-A offered  n = 28 
Never  0 
At least 1/year 0 
At least 2/year 0 
At least 1/ month 2 (7) 
At least 1/week 26 (93) 
Unsure 0 
Percentage of patients that elect PGT-A n = 28 
None 0 
1-10% 0 
11-25% 2 (7) 
26-50% 6 (21) 
51-75% 12 (43) 
76-100% 7 (25) 
Other 1 (4) 
Who conducts pre-test counseling for PGT-A (select all that apply) n = 28 
I do 25 
In house GC 3 
Contracted/ outside clinical GC 1 
PGS lab GC 5 
Other 2 
Percentage of those who elect PGT-A who are left with no euploid 
embryos but one or more mosaic embryos  n = 23 
None 0 
1-10% 15 (65) 
11-25% 2 (9) 
26-50% 0 
51-75% 1 (4) 
76-100% 0 
Unknown  5 (22) 










Frequency of PGT-A counseling n = 148 n = 46 n = 194 
Never 38 (25) 1 (2) 38 (20) 
At least 1/yr 20 (14) 4 (9) 24 (12) 
At least 2/yr 44 (30) 5 (11) 50 (26) 
At least 1/month 34 (23) 7 (15) 41(21) 
At least 1/week 12 (8) 29 (63) 41 (21) 
Timing of PGT-A counseling  n = 109 n = 44 n = 153 
Before testing 47 (43) 10 (23) 57 (37) 
After testing 22 (20) 7 (16) 29 (19) 
Both before and after testing 34 (31) 23 (52) 57 (37) 
It depends 5 (5) 4 (9) 9 (6) 
Other 1 (1) 0 1 (1) 
Table 3: GC experience regarding PGT-A  
Eighty-two percent of REs who offer PGT-A indicated that their clinic also offers transfer of 
mosaic embryos.  When asked if they had ever discussed the option of transferring a mosaic embryo with 
a patient, the majority of REs (87%) and infertility GCs (67%) said yes, while only 20% of non-
infertility GCs indicated that they had counseled on this topic (p<0.001). Of the 143 GCs who said they 
had not discussed this option, 31% specified it was because the situation had not presented itself. Non-
infertility GCs were more likely to say the opportunity had not presented itself (58%) than other GCs and 
infertility GCs were more likely to say transfer of mosaic embryos is against their/their referring clinic's 
policy (40%; p=0.012) than other GCs as the reason for why they have not seen a patient to discuss 
transfer of mosaic embryos. For the 59 GCs who had discussed the option to transfer a mosaic embryo, 
55 provided a response about the number of cases they had seen to discuss mosaic embryos and 53 
provided a response about the percentage of the patients that elected to transfer a mosaic embryos(s). Of 
the GCs who provided a response, the majority (41%) reported discussing mosaic embryos in a total of 
1-2 cases while infertility GCs most commonly indicated that they had seen greater than 20 cases (39%) 
(p<0.001) (Table 4). The majority of REs (40%) had seen 3-5 cases in which the option to transfer a 
mosaic embryo was discussed. Of the 53 GCs who provided a response about the percentage of the 
patients that elected to transfer a mosaic embryos(s), 43% indicated that they did not know what 
percentage of their patients elected to proceed with the transfer of mosaic embryo(s) or reported that 
information was unavailable while only 15% of REs indicated that information was unknown (p=0.02). 
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There was no significant difference between GCs who worked in an IVF clinic and those not working in 
an IVF clinic with regard to the percentage of patients who elected to transfer a mosaic embryo(s). REs 
most commonly (30%) selected 1-10% as the percentage of patients who decided to proceed with 
transfer of mosaic embryo(s) after discussing the option. There was no significant difference found 
between REs and infertility GCs responses on this question. When asked whether any of the patients who 
elected transfer of a mosaic embryo had a documented viable pregnancy (defined as a heartbeat noted on 
ultrasound), approximately one third (33%) of GCs were able to respond with an affirmative while the 
majority (55%) were unsure.  When further divided by specialty, infertility GCs were more likely (41%) 
to be aware of a documented heartbeat on follow up ultrasound compared to non-infertility GCs (24%).  
Conversely, 70% of REs were able to confirm viability of pregnancies following transfer of a mosaic 








Total GCs  
n (%) 
Who counsels post-test/pre-transfer 
(select all that apply) 
n = 23  n/a   n/a  n/a 
I do 12 - - - 
In house GC 7 - - - 
Contracted/ outside clinical GC 11 - - - 
PGS lab GC 10 - - - 
Other 1 - - - 
Number of cases to discuss TME  n = 20  n = 28 n = 27 n = 55 
1-2 6 (30) 7 (25) 16 (59) 23 (42) 
3-5 8 (40) 4 (14) 7 (26) 11 (20) 
6-10 1 (5) 5 (18) 1 (4) 6 (11) 
11-20 4 (20) 1 (4) 3 (11) 4 (7) 
>20 1 (5) 11 (39) 0 11 (20) 
Percentage of patients that elect to 
TME 
n = 20 n = 27 n = 26 n = 53 
none or 0%  0  5 (19) 5 (19.2) 10 (19) 
<10% 6 (30) 3 (11) 2 (7.7) 5 (9) 
10-25% 3 (15) 4 (15) 3 (11.5) 7 (13) 
26-50% 1 (5) 2 (7) 0 2 (4) 
51-75% 4 (20) 0 1 (3.9) 1 (2) 
76-100% 3 (15) 0 1 (3.9) 1 (2) 
other 0 3 (11) 1 (3.9) 4 (8) 
unknown/information unavailable  3 (15) 10 (37) 13 (50.0) 23 (43) 
Table 4: Practices and experiences regarding transfer of mosaic embryos 
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Figure 2 illustrates the identified factors and ranking of selected factors that are considered when 
prioritizing multiple mosaic embryos for transfer. The specific chromosome involved was the factor that 
was selected the greatest number of times within both groups (n=34, 62% of GCs and n=17, 94% of 
REs). The chromosome involved was also most frequently ranked as the most important factor by GCs 
(22%) while the level of mosaicism was most frequently ranked as the most important factor by REs 
(50%). When comparing factors selected between GCs, infertility only GCs are more likely to use which 
chromosome is involved (33%) and a published scoring system (25%) as factors than prenatal only GCs 
(9% and 3%, respectively) (p=0.01). 
 
Figure 2: Factors used to prioritize multiple mosaic embryos and rank 
 
Respondents were asked what prenatal testing and/or monitoring they recommend following 
transfer of mosaic embryos and were given a free text box to type in their answer. Figure 3 provides a 




Figure 3: Prenatal testing and/or monitoring recommendations following transfer of a mosaic embryo(s) 
Perspectives regarding education, consent, decision-making and clinical guidance  
Most respondents, regardless of whether they had personally discussed the option with a patient, 
felt as though transfer of mosaic embryos should be an option (60% of GCs and 81% of REs). Although 
the difference in GCs and REs was not significant, prenatal only GCs were significantly more likely to 
answer, “it depends” (32%) than to say “yes” when compared to infertility only GCs (15%) or 
preconception only GCs (25%) (p<0.001). The most common theme identified in these free text 
responses for those that selected “it depends” was that it depends on which chromosome is involved 
(36%). The second most common theme was that it depends on if there are any normal embryos 
available (26%). Some other free text themes identified included: only if they had genetic counseling, 
patient’s/family’s understanding of the risks and limitations, case by case/circumstantial and 
patient’s/family’s threshold for risk.   
All respondents were asked to indicate their comfort level discussing PGT-A and transfer of 
mosaic embryos. Eighty-six out of 92 prenatal only GCs, 20 out of 24 infertility only GCs, 63 out of 72 
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The following data is based on those who provided an answer for these questions. GCs who identified 
infertility as their only specialty (85%), followed by REs (74%) and then GCs reporting multiple 
specialties (49%) reported the highest comfort level when discussing PGT-A with those reporting the 
lowest amount of comfort being prenatal only GCs (31%) (p=0.002) as shown in Table 5. Similarly, 
infertility only GCs (55%), followed by REs (33%) and then GCs reporting multiple specialties (17%) 
reported the highest comfort level when discussing transfer of mosaic embryos with those reporting the 
lowest amount of comfort being prenatal only GCs (5%) (p<0.001). Overall, all respondents are more 
likely to report discomfort discussing transfer of mosaic embryos than discussing PGT-A itself 
(p=<0.001). Those who had seen more cases involving mosaic embryos reported more comfort 
















N = 174 
REs 
n (%) 
N = 27 
Comfort discussing PGT-A      
Extremely comfortable 17 (85) 31 (49) 27 (31) 78 (45) 20 (74) 
Somewhat comfortable 2 (10) 30 (48) 48 (56) 82 (47) 6 (22) 
Neither uncomfortable or 
comfortable 
0 1 (1.5) 6 (7) 7 (4) 0 
Somewhat uncomfortable 0 1 (1.5) 4 (5) 5 (3) 1 (4) 
Extremely uncomfortable 1 (5) 0 1 (1) 2 (1) 0 
Comfort discussing TME       
Extremely comfortable 11 (55) 11 (17) 4 (5) 26 (15) 9 (33.3) 
Somewhat comfortable 5 (25) 31 (49) 38 (44) 78 (45) 11 (40.7) 
Neither uncomfortable or 
comfortable 
1 (5) 6 (10) 15 (17) 22 (13) 1 (3.7) 
Somewhat uncomfortable 2 (10) 14 (22) 24 (28) 40 (23)  5 (18.5) 
Extremely uncomfortable 1 (5) 1 (2) 5 (6) 8 (4) 1 (3.7) 
Table 5: Comfort level discussing PGT-A and transfer of mosaic embryos  
Table 6 contains the results of a series of vignette questions that were posed to respondents where 
they were asked to provide their opinion. Following each vignette, they were asked whether their opinion 
about that situation was consistent with their clinic’s policy.  On average, there was a 90% response rate 
for GCs and 93% response rate for REs for all questions listed in Table 6. Approximately two thirds of 
all respondents (62%) agreed that the best time to discuss the possibility of having a mosaic embryo(s) 
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following PGT-A with a patient/couple is before the IVF cycle. Alternatively, 20% of GCs thought it 
should be discussed after IVF has started but before PGT-A is performed while zero REs selected the 
same option.  Twenty-two percent of REs indicated “after IVF and PGT-A has identified mosaic 
embryos” as the most ideal time while 14% of GCs indicated the same feeling. GCs and REs responses 
had a similar distribution among answer choices when asked about the most ideal time for patients to 
decide whether or not to transfer a mosaic embryo and obtain informed consent with about half of all 
respondents (46%) selecting “after IVF and PGT-A and only mosaic embryos remain” as the most 
appropriate time. The second most commonly selected answer was “after IVF and PGT-A identified 
mosaic embryos” (31%) followed by “before the IVF cycle” as the third most common response (12%). 
For the scenario where a euploid embryo does not survive thawing and only mosaic embryos remain, 
there was no statistical difference between all GCs and REs responses. Almost half of all respondents 
(49%) thought the most appropriate next step would be to stop the cycle and discuss the possibility of 
transferring a mosaic embryo for a future transfer date. A smaller group indicated that they think 
obtaining consent to thaw a mosaic embryo and proceed with transfer as planned would be the most 
appropriate next step (17%). Fifteen percent of respondents selected “unsure” while 19% selected 
“other”. Those who selected “other” were allowed to submit a free text response to elaborate. Five 
themes were identified from the free text responses which included: this decision should have already 
been made in previous conversations with the patient, discuss the possibility of another egg retrieval vs. 
transferring mosaic embryo(s), present both options (stopping the cycle or transferring mosaic embryo(s) 
right away) to the patient and let them decide, I don't think mosaics should be transferred/my clinic does 
not allow transfer of mosaic embryos, and no one correct answer in this scenario/decisions should be 
made on a case by case basis. One quarter of prenatal only GCs selected the option to obtain consent for 
transfer of a mosaic embryo(s) while none of the infertility only GCs thought obtaining consent and 
proceeding with transfer of mosaic embryos would be the most appropriate next step in this scenario. 
Instead, the majority of infertility only GCs (65%) selected to stop the cycle. This option was only 
selected by 40% of prenatal only GCs (p=0.007). In addition, GCs who see patients before and after 
PGT-A were more likely to “select stop the cycle” than GCs who see patients for PGT-A only before 
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testing or only after testing (p=0.04). There was no correlation found between when respondents thought 
was the ideal time to discuss the possibility of mosaic embryos and the most appropriate next step when 
a euploid embryo does not survive thawing and only mosaic embryos remain. 
REs were significantly more likely to report that their opinions were consistent with their clinic’s 
policy than GCs with regard to the ideal time to discuss the possibility of mosaic embryos with patients 
and the most appropriate next step after a euploid embryo does not survive thawing and only mosaic 
embryos remain (p<0.001). When looking at the topic of the ideal time for the patient to decide whether 
or not to transfer a mosaic embryo(s) and to obtain informed consent, there was no statistically 
significant difference between REs and infertility GCs regarding whether their opinion was consistent 
with their clinic’s policy. Additionally, GCs were more likely to report that their referring clinic does not 
have a policy or that they are unsure if their opinion was consistent with the clinic policy than REs 
(p=<0.001). GCs who work in IVF clinics were more likely report that their opinions were consistent 








Best time to discuss possibility of mosaic embryos n = 174 n = 27 
Never 0 0 
Before an IVF cycle begins 105 (60.3) 20 (74) 
After IVF but before PGT-A  35 (20.1) 0  
After IVF, PGT-A & mosaic embryos identified  25 (14.4) 6 (22) 
Other 4 (2.3) 1 (4) 
Unsure  5 (2.9) 0 
Answer to above consistency with clinic policy n = 174 n = 27 
Yes 39 (22.4) 17 (63) 
No 6 (3.4) 1 (4) 
We/they do not have a policy 85 (48.9) 9 (33) 
Unsure 44 (25.3) 0 
When decision should be made & informed consent obtained to 
TME 
n = 175 n = 27 
Never 0 0 
Before an IVF cycle begins 21 (12) 5 (18.5) 
After IVF but before PGT-A  10 (6) 0 
After IVF, PGT-A & mosaic embryos identified  52 (30) 10 (37) 
After IVF, PGT-A & only mosaic embryos  81 (46) 11 (40.7) 
Other 6 (3) 1 (3.7) 
Unsure  5 (3) 0 
Answer to above consistency with clinic policy n = 174 n = 27 
Yes 27 (16) 15 (56) 
No 5 (3) 2 (7) 
We/they do not have a policy 96 (55) 9 (33) 
Unsure 46 (26) 1 (4) 
Next step after euploid embryo does not survive thawing and 
only mosaic remain 
n = 174 n = 27 
Stop the cycle and discuss the possibility of mosaic transfer for a 
future transfer date 84 (48) 15 (55.6) 
Obtain consent to thaw a mosaic embryo and proceed with transfer 
as planned 30 (17) 4 (14.8) 
Other 31 (18) 7 (25.9) 
Unsure  29 (17) 1 (3.7) 
Answer to above consistency with clinic policy n = 173 n = 26  
Yes 12 (7) 12 (46) 
No 5 (3) 0  
We/they do not have a policy 96 (55) 12 (46) 
Unsure 60 (35) 2 (8) 




All respondents were asked to report how much difficulty they perceive their patients encounter 
when trying to understand and make decisions regarding PGT-A and transfer of mosaic embryos (Table 
7). On average, we received a 90% response rate for GCs and 93% response rate for REs for all 
questions regarding patients’ perceived difficulty. About half of GCs (47%) and REs (56%) perceive that 
their patients find it somewhat difficult to understand the benefits and limitations of PGT-A (Table 7). 
However, 29% of GCs indicated they think it is either somewhat easy or very easy for their patients 
while 19% of REs selected somewhat easy or very easy.  Those who reported more comfort discussing 
PGT-A were more likely to report that they perceived their patients had less difficulty understanding 
PGT-A (p=0.02).  Regarding patients’ perceived difficulty deciding whether to pursue PGT-A, 41% of 
both GCs and REs reported it appears somewhat easy for their patients while about one third (33%) of all 
respondents selected somewhat difficult.  
Providers perceive more difficulty for their patients to understand the benefits and limitations of 
transferring a mosaic embryo with 80% of both groups selecting either somewhat difficult or very 
difficult. Similar to PGT-A, those who reported more comfort discussing transfer of mosaic embryos 
were more likely to perceive that patients have less difficulty understanding this option (p=0.02).  
Interestingly, a provider’s comfort discussing transfer of mosaic embryos was not correlated with how 
much difficulty they perceived patients had deciding whether or not to elect transfer of mosaic embryos. 
Two percent of GCs and 11% of REs thought it was somewhat easy or very easy for their patients to 
decide whether to pursue transfer of a mosaic embryo(s) while 87% of GCs and 81% of REs indicated 
they think it is somewhat difficult or very difficult for their patients to make this decision. A moderate 
positive correlation was found between how much difficulty respondents perceived their patients 
encounter understanding benefits/limitations of PGT-A and perceived difficulty understanding 
benefits/limitations of transfer of mosaic embryos (rho=0.44, p<0.001). There was a weak correlation 
between perceived patient difficulty deciding whether to pursue PGT-A and difficulty deciding whether 
to transfer mosaic embryos (rho=0.23, p<0.001). The majority of respondents (77%) reported more 
patient difficulty with the decision whether or not to transfer mosaic embryos than the decision whether 
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or not to undergo testing initially. Lastly, a moderate positive correlation existed between how much 
difficulty respondents perceived their patients encounter understanding benefits/limitations of 
transferring mosaic embryos and perceived difficulty deciding whether to elect that transfer (rho=0.45, 
p<0.001).  
 GCs 
n (%)  
REs 
n (%)  
Understanding benefits/limitation of PGT-A n = 174 n = 27 
Very easy 1 (0.6) 3 (11.1) 
Somewhat easy 50 (28.7) 5 (18.5) 
Neither easy nor difficult 27 (15.5) 1 (3.7) 
Somewhat difficult 81 (47.8) 15 (55.6) 
Very difficult 10 (6.5) 3 (11.1) 
Unsure  5 (2.5) 0 
Deciding whether to pursue PGT-A n = 174 n = 27 
Very easy 4 (2) 2 (7.4) 
Somewhat easy 72 (41) 11 (40.7) 
Neither easy nor difficult 19 (11) 2 (7.4) 
Somewhat difficult 56 (32) 10 (37) 
Very difficult 8 (5) 2 (7.4) 
Unsure  15 (9) 0 
Understanding benefits/limitation of TME n = 173 n = 27 
Very easy 0  0 
Somewhat easy 17 (9.8) 2 (7.4) 
Neither easy nor difficult 9 (5.2) 2 (7.4) 
Somewhat difficult 89 (51.4) 13 (48.1) 
Very difficult 49 (28.3) 9 (33.3) 
Unsure  9 (5.2) 1 (3.7)  
Deciding whether to pursue TME n = 174 n = 27 
Very easy 1 (0.6)  0 
Somewhat easy 2 (01.1) 3 (11) 
Neither easy nor difficult 8 (4.6) 2 (7) 
Somewhat difficult 56 (32.2) 8 (30) 
Very difficult 95 (54.6) 14 (52) 
Unsure  12 (6.9) 0 
Table 7: Patient education and decision-making  
Figure 4 summarizes the resources reported as influential to providers’ personal feelings and/or 
clinical practice with regard to transfer of mosaic embryos. The resource that influenced the greatest 
number of respondents was the PGDIS position statement published in 2016 (75%) followed by 
laboratory reporting policies (71%). However, 60-80% of those who reported that the PGDIS position 
22 
 
statement influenced their practice did not select the factors it recommended for prioritization of mosaic 
embryos (which chromosome is involved, trisomy vs. monosomy and the level of mosaicism). The 
resource that was most commonly reported to have no influence was personal practice experience (30%). 
Between most of the articles/position statements (except the PGDIS position statement), there was a 
comparable percentage of respondents who indicated they had not read that resource (35-45%). There 
was also a comparable percentage of respondents who indicated that the resource influenced them across 
the various articles/position statements listed (45-55%). Additionally, there was a small group of 
respondents (less than 10%) who indicated they had read the resource and it did not influence them. 
From this, we could infer that among those who had read a resource, the vast majority of them felt it 
influenced them in some way. 
 




Lastly, the respondents were asked to indicate whether they believe additional consensus/guidance 
is needed for a list of various topics regarding transfer of mosaic embryos (Figure 5). Depending on the 
topic in question, a large majority of respondents (67-84%) indicated that additional consensus/guidance 
is needed. Of note, 20% of respondents indicated that they thought no additional consensus/guidance is 
needed regarding when to discuss the possibility of mosaic embryos or when to consent for transfer of 
mosaic embryos. Those who indicated that no additional guidance was needed for these two topics were 
more likely to say they thought patients found it very easy or somewhat easy to decide whether to 
transfer mosaic embryos (p<0.001). Within two of the topics listed (prioritization when multiple mosaic 
embryos are present and the appropriate number of mosaic embryos to transfer), those who reported 
higher levels of comfort discussing transfer of mosaic embryos were more likely to report that they do 
not think additional consensus or clinical guidance is needed (p<0.005). However, there was no 
correlation between those who indicated additional consensus and/or guidance was needed and comfort 
level discussing transfer of mosaic embryos on these two topics.  
 





Limited published guidance along with a lack of formal consensus regarding the transfer of 
mosaic embryos after IVF with PGT-A presents a complex clinical scenario for providers who are 
responsible for helping patients to understand their options and make reproductive decisions. The current 
study was conducted to describe the current practices regarding transfer of mosaic embryos, as reported 
by GCs and REs. Additionally, we aimed to determine GC and RE professional perspectives on patient 
education, informed consent, decision making and clinical guidance with regard to the transfer of mosaic 
embryos. The results show that overall, these providers desire additional consensus to help guide their 
practice. 
Evaluating current practices of the GCs and REs that responded to the survey revealed a theme 
regarding the interaction between infertility GCs and REs. Namely, responses revealed that infertility 
GCs’ experience and practices are more consistent with REs than with GCs of other specialties. 
Infertility GCs and REs working together and their relatively more frequent experience with PGT-A 
cases and results compared to non-infertility GCs could explain the similarities in their practices. 
Infertility GCs often differed from their prenatal colleagues in terms of the variability in responses with 
more variability among prenatal GCs. This could be due to less frequent experience with counseling 
about mosaic embryos and less familiarity with newly published data in this area among prenatal GCs. 
REs reported utilizing GCs more often for post-test/pre-transfer counseling than for pre-test counseling, 
whether that might be a lab GC, outside/contracted clinical GC or in-house GC. This may be a reflection 
of the lower levels of comfort among REs who participated in the study when counseling about mosaic 
embryos compared to counseling about PGT-A.  
There were only two of six topics regarding transfer of mosaic embryos posed to respondents 
(prioritization of multiple mosaic embryos and the appropriate number of mosaic embryos to transfer) 
that had a statistically significant relationship between whether respondents thought additional guidance 
was needed on that topic and a providers’ comfort level discussing transfer of mosaic embryos. Those 
reporting a lower level of comfort discussing transfer of mosaic embryos were more likely to be unsure 
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of whether additional guidance was needed on certain topics. It is hypothesized that those who were 
unsure may be less familiar with transfer of mosaic embryos and therefore, have not formed an opinion 
about whether additional guidance is needed. However, no correlation between the number of mosaic 
cases seen and comfort level discussing transfer of mosaic embryos was seen. Those who had higher 
levels of comfort discussing transfer of mosaic embryos were more likely to indicate that they did not 
think additional guidance was needed. However, even within these two topics, there was no statistically 
significant difference amongst those who indicated additional guidance was needed and comfort level 
discussing transfer of mosaic embryos. For all of the other four topics listed, there were no correlations 
found between comfort level and whether additional guidance was needed. Therefore, regardless of 
current practices and comfort level discussing transfer of mosaic embryos, the large majority of 
respondents agreed that additional consensus and clinical guidance is needed regarding how to 
appropriately counsel and manage cases involving mosaic embryos. This was reflected when analyzing 
how respondents prioritize multiple mosaic embryos when several are available for transfer. Although 
the REs had some consistency in their responses, there was no clear trend that indicated that GCs and 
REs have any set criteria or consensus for how they are prioritizing multiple mosaic embryos for 
transfer.  
Responses regarding the influence of several applicable resources regarding transfer of mosaic 
embryos showed that the majority of providers who read publications on this topic feel as though those 
resources influenced their practice in some regard. Interestingly, the majority of those indicating that the 
PGDIS position statement influenced them did not report using the factors recommended in this position 
statement for prioritization. One possibility is that these resources influenced them in the past, but they 
no longer abide by these recommendations given conflicting data that has been published since the 
recommendations were established. Another possible explanation would be that the guidelines were 
misinterpreted by readers or were unclear in their recommendations. Respondents were asked whether 
the resources listed influenced them at all but were not specifically asked if they influenced them in 
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regard to each specific factor. Therefore, it is possible that respondents did feel like the PGDIS position 
statement influenced them but not in a way that aligned with its recommendations. 
One aim was to identify how comfortable or confident respondents report feeling when 
counseling about PGT-A and transfer of mosaic embryos. The order of groups reporting the most 
comfort counseling to least comfort was consistent between these two topics. Infertility GCs were the 
most consistently comfortable group followed by REs, with non-infertility GCs most commonly 
reporting more discomfort. However, across all respondents, less comfort was reported regarding 
counseling about transfer of mosaic embryos compared to PGT-A. This may be due to less experience 
with cases involving mosaic embryos and/or limited consensus and clinical guidance on this topic 
compared to PGT-A. Regardless of the cause, this finding identifies an area for additional studies and 
proposed guidelines to help providers feel more confident counseling their patients. This study identified 
that a provider’s comfort level discussing a topic is correlated with how much they think their patients 
struggle to understand that topic. Additionally, providers’ perceptions about the level of difficulty their 
patients face through the IVF process reflected that the decision whether to use mosaic embryos was 
more challenging than decisions about whether to pursue testing of embryos.   
Although the majority of respondents felt that the option of transferring mosaic embryos should 
be available, prenatal only GCs were less likely to simply answer “yes”. They were more likely to 
respond that it would depend on particular variables and cited specific circumstances including, which 
chromosome is involved, if there are any euploid embryos available, whether the patient has had genetic 
counseling and the patient’s threshold for acceptability and risk. However, infertility only GCs did not 
share the sense that it is conditional and more commonly indicated it should be an option outright. 
Prenatal GCs’ feelings on this topic could be attributed to their relatively less frequent experience and 
lower comfort with cases involving mosaic embryos. The presence of a willingness to accept risks 
associated with new IVF treatments among infertile patients’ in order to achieve a pregnancy has been 
described previously (Hartshorne et al., 2002). This willingness accompanied by the physical, emotional, 
psychological and financial burden that these patients accept throughout the IVF process demonstrates 
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how invested these patients are in their efforts to have a child. Given that infertility GCs work with this 
patient population more frequently than non-infertility patients, they may be more conditioned to their 
patients electing new reproductive options that have limited research and feel more comfortable about 
offering something less proven such as transfer of mosaic embryos.   
There was less consensus among respondents when they were asked about the ideal time to 
counsel patients on the possibility of mosaic embryos, decide whether to transfer mosaic embryos, and 
obtain informed consent, as well as the most appropriate next step when a euploid embryo does not 
survive thawing and only mosaic embryos remain. Two thought processes emerged from these responses 
that can be differentiated by how much emphasis is placed on anticipatory guidance. One thought 
process is that the possibility of mosaic embryos does not need to be discussed and decisions on whether 
to transfer mosaic embryos do not need to be made until the patient is in that situation rather than having 
a discussion and deciding prior to beginning the IVF cycle. These respondents may feel that it is not 
necessary or efficient to have this conversation with all their patients who pursue PGT-A since a 
minority of them will only have mosaic embryos after testing. Furthermore, one with this thought 
process could argue the efficacy/utility of this anticipatory decision making since patients could change 
their minds after testing identifies mosaic embryos even if they had made a tentative decision prior to 
testing. Conversely, the other thought process gleaned from these questions is one with a greater 
emphasis on making patients aware of the concept/possibility of mosaic embryos prior to testing and 
having patients determine their preference whether or not to utilize mosaic embryos before the IVF 
cycle. This theoretically allows the patient to weigh their options more logically and rationally compared 
to placing this decision on the patient during an IVF cycle where they may be experiencing mood 
changes as a side effect of their treatment (Wallach et al., 1982). This raises a question regarding 
informed consent of this vulnerable population who already carries a psychological burden when asked 
to make these high stakes decisions with limited time (Besser et al., 2017). Whether GCs see these 
patients before or after testing may influence their feelings about when these conversations should be had 
since they may not have the opportunity to see these patients at multiple time points (before and after 
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testing). This was demonstrated with regard to the most appropriate step in the scenario that a euploid 
embryo(s) does not survive the thawing process and only mosaic embryos remain. Those seeing patients 
before and after testing were more likely to think they should stop the cycle. GCs may feel more strongly 
about the importance of providing anticipatory guidance. Furthermore, REs may view their patients as 
being more resilient and capable of making these critical decisions than GCs. The question of the amount 
of importance that should be placed on the timing of these discussions with patients’ needs to be 
explored further by those practicing in this field with the goal of creating a broader consensus. It will 
also be imperative to assess patient experiences and preferences to determine when and how they would 
like to be presented with information.  
GCs were identified as being more likely to report that they are unsure if their opinions regarding 
the appropriate timing and actions regarding transfer of mosaic embryos is consistent with the clinic’s 
policy compared to REs.  Some possible reasons for this uncertainty could be a lack of clarity and 
transparency of the IVF clinic’s policies or limited communication between referring REs and their 
contracted/outside GC providing counseling to the patient. This shows a need for more communication 
between REs and GCs who are working together. It is imperative for GCs to at least be aware of the 
clinic’s policies, if not also being involved in creating such policies, so as not to provide 
conflicting/misleading information in the counseling session as that could lead to confusion, frustration 
and/or disappointment for patients. 
Future research should investigate patients’ perspectives on transfer of mosaic embryos. Ideally, 
a paired study with the patient and their provider could be conducted with a survey before and after PGT-
A as well as before and after transfer of a mosaic embryo(s). This would allow researchers to compare 
provider and patient perspectives and provide valuable insight into best practices. Further studies could 
help provide an evidence-based approach to care for patients who are identified to have mosaic embryos 
after IVF and PGT-A. Presently, there may be barriers to conducting this research such as availability of 
data from IVF centers and from providers. Given that there may be multiple providers involved in the 
care of one patient throughout the IVF and PGT-A process, there needs to be efforts to determine how 
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these providers can collaborate to collect and organize data regarding how these patients were counseled, 
their decisions and outcomes.  
Our study limitations had a significant impact on our ability to detect certain differences between 
groups and the generalizability of our results. One such limitation of this study was the low statistical 
power due to the total number of respondents and the comparatively few REs compared to GCs. Unlike 
the GCs, REs were unable to be reached by listserv and instead were contacted personally via email by 
the principal investigator or by a GC that forwarded them the survey. Allowing GCs to forward the 
survey to REs they work with helped to collect responses but does introduce a bias in the RE cohort. The 
REs included in this study may be more likely to work with or know a GC and therefore, their responses 
may not be generalizable to all REs. Additionally, the majority of RE respondents’ practice in Texas with 
a low response rate from other states which may make it more difficulty to generalize these results to all 
REs. Since the survey was anonymous, we were unable to determine whether or not we received multiple 
RE responses from the same clinic. This represents the potential that our RE cohort is more 
homogeneous than the general RE population. The RE responses are further limited given that 9 were 
fellows with limited experience and clinical judgment. Additionally, it is unclear what percentage of 
practicing REs and RE fellow responded to the survey.  As such the description of experience with, 
approaches to and views on the topics of the study may only be truly representative of the select group of 
REs who responded to the survey and not the larger RE population.  The prenatal GC cohort in this study 
constituted a larger percentage of the overall GC cohort than what is reported in the NSGC PSS 
published in 2018. However, the proportion of GCs identifying as preconception was comparable with 
the PSS. Additionally, the survey tool used for this study was not validated; therefore, there was a 
potential for questions to be interpreted differently than intended. Given the low response rates within 
GC and RE cohorts, we recognize that these results may not be representative of these provider groups 
practices and perspectives regarding transfer of mosaic embryos. These results represent a small 
sampling of these groups to provide a platform for discussion and further research.  
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In conclusion, this research shows that providers report feeling less comfortable counseling 
patients regarding transfer of mosaic embryos than with pre-test PGT-A counseling. Additionally, there 
may be limited consensus among providers regarding their practices and perspectives surrounding 
transfer of mosaic embryos. The majority of these providers felt that additional consensus and clinical 
guidance is needed about how to counsel these patients and the appropriate timing for specific events in 
the counseling process such as patient education and informed consent. Additional research elucidating 
both patient and provider perspectives along with additional data about clinical outcomes of these 
transfers may help lead to a consensus in this community and therefore provide opportunities for the 
development of additional clinical guidance. A more consistent and evidence-based approach to patient 
care regarding counseling about and transfer of mosaic embryos could lead to better outcomes, more 
satisfied patients and could seek to minimize ethical conflicts for both patients and providers related to 






*= answer required 
Demographics - All 
Q1. Consent 
1. I agree 
2. I do not agree >>> exit survey 
Q2. What is your current area of practice? * 
1. Prenatal and/or Infertility Genetic Counselor 
2. Reproductive Endocrinologist  
3. None of the above >>> Thank you for your participation 
Q3. In what state do you currently practice?  
1. Drop down with states/DC/I do not practice in the United States/Prefer not to answer 
 
GC Experience - Genetic Counselor (GC) 
Q4. How would you describe your work setting? (Select all that apply)  
1. Academic institution 
2. Non-academic institution 
3. Private practice 
4. IVF clinic 
5. Other (free text option) 
Q5. How many total genetic counselors work in your clinic/department/practice within your 
specialty? (free text box) 




4. Other (free text option) 
Q7. How many total years have you spent providing prenatal, preconception and/or infertility 
counseling? (response requested if left blank) 
 
Definition of PGS/PGT-A: Preimplantation genetic screening (PGS) or Preimplantation genetic 
testing for aneuploidy (PGT-A) refers to genetic testing of embryos for chromosomal 
abnormalities following IVF and prior to embryo transfer. It will be referred to as PGS/PGT-A 
throughout the remainder of the survey. 
 
Q8. Select the option that best describes how often you personally see preconception patients to 
discuss preimplantation genetic screening/testing for aneuploidy (PGS/PGT-A)? * 
1. Never 
2. At least once per year 
3. At least twice per year 
4. At least once per month 
5. At least once per week 
6. Other (free text option) 
All that answered something other than ‘never’ continue to 5a 
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Q9. When do you typically see patients to discuss PGS/PGT-A?  
1. Before testing 
2. After testing 
3. Both 
4. It depends (please describe in the space provided) 
5. Other (free text option) 
 
Definition of mosaicism: the presence of two or more different chromosome complements within an 
embryo that developed from a single fertilized egg.  
Q10. Have you ever personally seen a patient to discuss the option of transferring a mosaic 
embryo(s) following PGS/PGT-A? * 
1. Yes 
2. No 
Q11. [If yes] Approximately what how many total cases have you seen to discuss the transfer of a 





5. More than 20 
Q12. [if yes conti] If you have been in the situation where there are multiple mosaic embryos 
available, what factors do you consider when prioritizing which mosaic embryo(s) to transfer? 
(Select all that apply)  
1. Level of mosaicism 
2. Trisomy vs. monosomy 
3. Whole vs. partial chromosome (deletion/duplication) involved 
4. Which chromosome is involved 
5. Published scoring system 
6. Internal scoring system 
7. Other  (free text option) 
8. Unsure 
9. I have not been in a situation where there are multiple mosaic embryos available 
10. I do not advise the RE on which embryo(s) to consider for transfer 
Q13. Please rank (if multiple) the factors selected in the previous question that you consider when 
prioritizing mosaic embryos from most important (1) to least important. (Carries over items 
selected in previous question) 
Q14. [If yes conti] Approximately what percentage of the patients with whom you have discussed the 
option of transferring a mosaic embryo(s) following PGS/PGT-A elected to proceed with the 







7. Other (free text option) 
8. Unknown/information not available 
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Q16. [If transfer of mosaic embryo] What monitoring and/or testing did you recommend for these 
pregnancies? (free text box) 
Q17. [if no] Please indicate what factors keep you from seeing patients to discuss the transfer of 
mosaic embryos?    
1. Transfer of mosaic embryos is against our/our referring providers’ policy 
2. The opportunity (mosaic results after PGS/PGT-A) hasn’t presented itself yet 
3. Our reference lab does not report mosaicism 
4. Other (free text option) 
5. Unsure 
 
RE Experience - Reproductive Endocrinologist (RE)  
Q18. How many years have you practiced as an RE post-fellowship? (response requested if left 
blank)  
1. (free text box) 
2. I am currently a fellow 
Q19. How many total REs are there in your current clinic/practice? (free text box) 
 
Definition of PGS/PGT-A: Preimplantation genetic screening (PGS) or Preimplantation genetic 
testing for aneuploidy (PGT-A) refers to genetic testing of embryos for chromosomal 
abnormalities following IVF and prior to embryo transfer. It will be referred to as PGS/PGT-A 
throughout the remainder of the survey. 
 
Q20. Does your clinic/practice offer patients the option of preimplantation genetic 
screening/preimplantation genetic testing for aneuploidy (PGS/PGT-A) to screen for 
chromosome abnormalities? *  
1. yes 
2. no 
Q21. [If yes] Under what circumstances do you personally offer PGS/PGT-A? 
1. I offer PGS to all patients 
2. I offer PGS to all patients of a certain age 
3. I only offer PGS to patients who meet specific criteria (e.g. history of recurrent 
pregnancy loss, history of failed embryo transfers) 
4.  I never offer PGS 
Q22. [If yes] Select the option that best describes how often you personally offer PGS/PGT-A? 
1. None 
2. At least once per year 
3. At least twice per year 
4. At least one per month 
5. At least once per week 
6. Other (free text option) 
7. Unsure 
Q23. [If yes, conti] Approximately what percentage of your patients to whom you offer PGS/PGT-A, 









7. Other (free text option) 
8. Unknown/information not available 
Q24. [If yes conti] Who typically provides the PGS/PGT-A pre-test counseling for your patients? 
(Select all that apply)  
1. I do 
2. An in-house genetic counselor 
3. (contracted/outside clinical genetic counselor) 
4. (PGS/PGT-A laboratory genetic counselor) 
5. other (free text option) 
Q25. [If no] Please indicate what factors keep you from offering PGS/PGT-A: (select all that apply) 
1. Clinic policy 
2. Personal or professional preference 
3. Clinic’s inability to perform embryo biopsy 
4. Other (free text option) 
5. Unsure 
 
If they answered yes to #3 above (They do offer PGS/PGT-A). 
Definition of mosaicism:  the presence of two or more different chromosome complements 
within an embryo that developed from a single fertilized egg.  
Q26. Have any of your personal patients received a PGS/PGT-A report with zero normal embryos 




Q27. [If yes] Approximately what percentage of your patients who pursue PGS/PGT-A are left with 







7. Other (free text option) 
8. Unknown/information not available 
Q28. Does your clinic/practice offer the option of transferring a mosaic embryo(s)? *  
1. Yes 
2. No 
Q29. [if yes] Who typically provides the post-test/pre-transfer counseling? (Select all that apply)  
1. I do 
2. An in-house genetic counselor 
3. (contracted/outside clinical genetic counselor) 
4. (PGS/PGT-A laboratory genetic counselor) 
5. other (free text option) 
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Q30. [if yes conti] Have you personally discussed the option to transfer a mosaic embryo with one of 
your patients? *  
1. Yes  
2. No 
Q31. [If yes] Approximately how many times have you discussed the option to transfer a mosaic 





5. More than 20 
Q32. [If yes conti] Of the patients with whom you discussed the option to transfer a mosaic 
embryo(s), approximately what percentage of these patients elected to proceed with transfer of 







7. Other (free text option) 
8. Unknown/information not available 





Q34. [If transfer of mosaic embryo(s)] What, if any, additional monitoring and/or testing did you 
recommend for these pregnancies? (free text box) 
Q35. [if yes conti] If you have been in the situation where there are multiple mosaic embryos 
available, what factors do you consider when prioritizing which mosaic embryo(s) to transfer? 
(Select all that apply)  
1. Level of mosaicism 
2. Trisomy vs. monosomy 
3. Whole vs. partial chromosome (deletion/duplication) involved 
4. Which chromosome is involved 
5. Published scoring system 
6. Internal scoring system 
7. Other (free text option) 
8. Unsure 
Q36. I have not been in a situation where there are multiple mosaic embryos Please rank (if multiple) 
the factors selected in the previous question that you consider when prioritizing mosaic 
embryos from most important (1) to least important.  
Q37. [if no] To your knowledge, has any other RE in your practice offered the transfer of a mosaic 




4. I am the only RE in my practice 
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Q38. [if no] Please indicate what factors keep you from offering the transfer of mosaic embryos: 
(please select all that apply) 
1. Clinic policy 
2. I think the risk is too high 
3. I am concerned about liability 
4. I do not think patients understand the risks 
5. The lab we use doesn’t report/we do not request that information 
6. Other 
7. Unsure 
Patient Education/Confidence/Decision-Making/Informed Consent– All – Please answer the following 
questions even if you have never discussed the transfer of mosaic embryos with a patient 
Q39. Regardless of whether you have offered/discussed the option of transfer of a mosaic embryo(s) 




3. It depends  (free text option) 
4. Unsure 
Q40. How comfortable do you/would you feel discussing PGS/PGT-A in general with your patients?  
1. Extremely comfortable   
2. Somewhat comfortable   
3. Neither comfortable nor uncomfortable  
4. Somewhat uncomfortable   
5. Extremely uncomfortable   
Q41. How comfortable do you/would you feel discussing the option of transferring a mosaic embryo 
with your patients? 1-5 scale 
Q42. Ideally, when do you feel the possibility of having a mosaic embryo(s) following PGS/PGT-A 
should be discussed with a patient/couple?  
1. Never 
2. Before an IVF cycle begins 
3. After the IVF cycle has started but before PGS/PGT-A testing has been performed 
(before the egg retrieval) 
4. After the IVF cycle and PGS/PGT-A is complete and mosaic embryos are identified 
5. Other 
6. Unsure 
Q43. Is this consistent with your clinic/practice/referring practice’s policy?  
1. Yes 
2. No 
3. We/they don’t have a policy 
4. Unsure 
Q44. Ideally, when do you feel the decision should be made and informed consent obtained whether 
or not to transfer a mosaic embryo following PGS/PGT-A?  
1. Never 
2. Before an IVF cycle begins 
3. After the IVF cycle has started but before PGS/PGT-A testing has been performed 
(before the egg retrieval) 
4. After the IVF cycle and PGS/PGT-A is complete and mosaic embryos are identified 
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5. After the IVF cycle and PGS/PGT-A testing is complete and only mosaic embryos (but 
no normal) are identified 
6. Other 
7. Unsure 
Q45. Is this consistent with your clinic/practice/ referring practice’s policy?  
1. Yes 
2. No 
3. We/they don’t have a policy 
4. Unsure 
Q46. In your opinion, if a euploid (normal) embryo does not survive thawing, and only mosaic 
embryos remain, what is the most appropriate next step?  
1. Stop the cycle, and discuss the possibility of mosaic transfer for a future transfer date 
2. Obtain consent to thaw a mosaic embryo and proceed with transfer as planned 
3. Other (free text option) 
4. Unsure 
Q47. Is this consistent with your clinic/practice/ referring practice’s policy?  
1. Yes 
2. No 
3. We/they don’t have a policy 
4. Unsure 
Q48. In your opinion, how difficult do/would your patients find it to understand the benefits and 
limitations of PGS/PGT-A?  
1. Very easy 
2. Somewhat easy 
3. Neither easy nor difficult 
4. Somewhat difficult 
5. Very difficult 
6. Unsure  
Q49. In your opinion, how difficult do/would your patients find it to decide whether or not to pursue 
PGS/PGT-A? Difficulty likert scale  
Q50. In your opinion, how difficult do/would your patients find it is to understand the benefits and 
limitations to transfer a mosaic embryo(s)? Difficulty likert scale  
Q51. In your opinion, how difficult do/would your patients find it to decide whether or not to transfer 
a mosaic embryo(s)? Difficulty likert scale 
 
Clinical Guidance– All – Please answer the following questions even if you have never discussed the 
transfer of mosaic embryos with a patient 
Q52. How much, if at all, have the following influenced your personal feelings and/or clinical 
practice with regard to the transfer of mosaic embryos? Influence likert scale (no 
influence/minimal influence/moderate influence/significant influence/unsure/have not read) 
1. 2016 Preimplantation Genetic Diagnosis International Society (PGDIS) position 
statement – summary: Providers can consider transfer of a mosaic embryo(s) when 
there are no non-mosaic euploid embryos and no option for undergoing another IVF 
cycle. Recommended prioritization criteria (if multiple mosaic embryos are identified) 
include monosomies are preferred to trisomies, percentage of abnormal cells, and which 
chromosome is involved in the abnormal cell line (mosaicism involving specific 




2. 2016 Controversies in Preconception, Preimplantation and Prenatal Genetic 
Diagnosis (CoGEN) position statement – summary: consistent with PGDIS position 
statement outlined above 
3. 2017 Besser et al. commentary (RBMO) – summary: First commentary to address pre-
and post-test genetic counseling considerations, as well as prenatal screening and 
diagnosis considerations. 
4. 2018 Grati et al. paper (RBMO) – summary: Proposes an evidence-based scoring 
system (specific risk for each specific chromosome) based on prenatal samples for 
prioritizing mosaic aneuploid embryos for transfer. 
5. Other published statements/guidelines (open response) 
6. Case reports of transfers of mosaic embryos (including NEJM 2015 letter to the editor) 
7. Personal/practice experience of successful outcomes 
8. Patient request 
9. Laboratory reporting policies (ex. identifies and reports mosaic embryos, discloses level 
of mosaicism, etc.) 
10. Other (free text option) 
11. Other (free text option) 
12. Other (free text option) 
 
Q53. For which, if any, of the below topics do you believe additional consensus/guidance is needed? 
(additional consensus/guidance needed, no additional consensus/guidance needed or unsure) 
1. When to discuss the possibility of mosaic embryo transfer 
2. When to obtain patient consent for transfer of mosaic embryo 
3. How to appropriately counsel patients about the transfer of mosaic embryos 
4. Prioritization of mosaic embryos for transfer 
5. How many mosaic embryos to transfer at a time  
6. Prenatal testing and prenatal management recommendations following transfer of 
mosaic embryo(s) 
7. Other (free text option) 
8. Other  (free text option) 




Q54. Please provide any general comments regarding your opinions and/or experiences with transfer 
of mosaic embryos (free text box) 
Q55. Please enter your email address if you would like to be included in the gift card raffle (free text 
box) 
 
Invitation to forward to REs – All  
Q56. If you are aware of any reproductive endocrinologists that may be willing to participate, we 
invite you to forward the survey link to them (http://bit.ly/mosaic-embryos). If you would 
prefer, you may provide their email address(es) in the text box below, allowing the study 
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